| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-05-06 | Kymab (UK) | US $90 million (€80.45 million) | series B financing round | The Wellcome Trust (UK) the Bill & Melinda Gates Foundation (USA) Woodford Patient Capital Trust (UK) Malin Corporation (UK) | Infectious diseases | Series B financing round |
| 2015-05-05 | GW Pharmaceutical (UK) | $179.2 million | private placement | CNS diseases - Neurological diseases | Private placement | |
| 2015-05-05 | Blueprint Medicines (USA - MA) | $168.6 million | IPO | Cancer - Oncology - Genetic diseases | IPO | |
| 2015-05-05 | Themis Bioscience (Austria) | € 7 million | series B financing round | Wellington Partners (Germany - UK) Omnes Capital (formerly Crédit Agricole Private Equity) (France) - Ventech (France) | Infectious diseases | Series B financing round |
| 2015-05-05 | Inovio Pharmaceuticals (USA - PA) | $82.1 million | private placement | Cancer - Oncology - Infectious diseases | Private placement | |
| 2015-05-01 | Oxford Biomedica (UK) | $50 million | loan | Oberland Capital Healthcare (USA - NY) | Cancer - Oncology - Rare diseases - Ophtalmological diseases | Loan |
| 2015-05-01 | Horizon Discovery (UK) | £25 million | private placement | Technology - Services | Private placement | |
| 2015-04-30 | Newron Pharmaceuticals (Italy) | CHF 24.3 million (€ 23.2 - $ 25.5 million) | capital increase | current institutional shareholders and institutional investors from Europe and the U.S., including J.P. Morgan Asset Management (USA), Aviva (UK), Investor AB (Sweden) Sphera Global HealthCare Fund (Israel) Nyenburgh (The Netherlands) | CNS diseases - Neurological diseases - Neurodegenerative diseases | Capital increase |
| 2015-04-30 | Pfenex (USA - CA) | $38 million | private placement | Private placement | ||
| 2015-04-29 | CRISPR Therapeutics (Switzerland) | $ 89 million | series B financing round | SR One (UK) Celgene (USA - NJ) New Enterprise Associates (NEA) (USA - MD) Abingworth (UK) Versant Ventures (USA - CA) | Genetic diseases - Rare diseases | Series B financing round |
| 2015-04-29 | Stemcells (USA - CA) | $25 million | private placement | Rare diseases - Regenerative medicine | Private placement | |
| 2015-04-29 | cytena (Germany) | € 1.1 million | financing round | High-Tech Gründerfonds (HTGF) (Germany) private investor | Technology - Services | Financing round |
| 2015-04-29 | Epigenomics (Germany - USA) | € 2.77 million | grant | European Commission’s Horizon 2020 programme | Cancer - Oncology - Diagnostic | Grant |
| 2015-04-27 | Pep Therapy (France) | €1.3 million | financing round | Seventure Partners (France) Bernard Majoie (France) | Cancer - Oncology | Financing round |
| 2015-04-25 | Ose Pharma (France) | € 21.1 million | IPO | Cancer - Oncology | IPO | |
| 2015-04-23 | Nordic Nanovector (Norway) | NOK 575 million (€ 66.6 million) | IPO | Cancer - Oncology - Rare diseases | IPO | |
| 2015-04-23 | Biotie Therapies (Finland) | € 95 million | capital increase, IPO | Vivo Capital (USA - CA) OrbiMed (USA - NY) Versant Ventures (USA - CA) Baupost Group (USA - MA) | Neurodegenerative diseases - CNS diseases | IPO |
| 2015-04-21 | Sage Therapeutics (USA - MA) | $138 million (€128.4 million) | private placement | CNS diseases - Neurological diseases | Private placement | |
| 2015-04-21 | Dimension Therapeutics (USA - MA) | $65 Million | series B financing round | New Leaf Venture Partners (USA - NY - CA) Jennison Associates Partner Fund Management (USA) RA Capital Management (USA - MA) Rock Springs Capital (USA - MD) Tourbillon Global Ventures (USA) Fidelity Biosciences (USA - MA) OrbiMed (USA - NY) | Rare diseases - Genetic diseases | Series B financing round |
| 2015-04-21 | Sensorion (France) | € 8.2 million | IPO | Otorhinolaryngology | IPO |
